A complex of clinical and immunochemical studies was made in patients with chronic brain ischemia and ischemic stroke and in neonatal infants with CNS dysfunctions and retarded intrauterine development. Enzyme immunoassay was used to measure the levels of brain proteins with trophic properties--S100b, the major protein myelin, lectins CSL, R1, and the levels of primary and antiidiotypic antibodies to these proteins in the biological fluids of the patients. The findings suggest that the study brain proteins and autoimmune processes against these factors are involved in the mechanisms of the pathogenesis of the diseases in question and they enable changes and variations in the levels of neurotropic factors and their autoantibodies to be considered as predictors of brain ischemia and perinatal cerebral lesions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study.
RMD Open
January 2025
Rheumatology and Translational Immunology Research Laboratories (LaRIT), Department of Internal Medicine and Therapeutics, Universita di Pavia, Pavia, Italy.
Objective: To delineate, within the framework of current clinical practice and criteria, the sustainability of first-line immuno-suppressive treatment discontinuation in rheumatoid arthritis (RA) and the impact of residual disease in remission on long-term drug-free (DF) outcomes.
Methods: RA patients, referring to the Pavia early arthritis clinic (EAC) between 2009 and 2021 and achieving remission after Disease Activity Score-driven methotrexate (MTX) monotherapy, were recruited. Eligible patients underwent DF follow-up at 3-month intervals over 5 years after MTX discontinuation.
Introduction: Type 1 diabetes is often accompanied by autoimmune thyroid disease. We aimed to investigate the clinical characteristics of Japanese patients with acute-onset type 1 diabetes and thyroid autoantibodies, focusing on decreased endogenous insulin secretion.
Materials And Methods: We examined 80 patients with acute-onset type 1 diabetes, classifying them into two groups with and without thyroid autoantibodies and compared the clinical characteristics of the two groups.
Mitochondrial DNA 3243 mutation may be associated with positivity of zinc transporter 8 autoantibody in cases of slowly progressive type 1 diabetes mellitus.
Diabetol Int
January 2025
Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, 38 Morohongo, Moroyamamachi, Iruma-Gun, Saitama, 350-0495 Japan.
Slowly progressive type 1 diabetes mellitus (SPIDDM), solely positive for zinc transporter 8 autoantibody (ZnT8A) is rare, and the factors involved in the single positivity remain largely unknown. Thus, this case report aimed to infer the factors based on a literature review. A 40-year-old female was hospitalized for hyperglycemia.
View Article and Find Full Text PDFMyricetin exposure reduces PC differentiation in vitro in primary human B cells.
Mol Med
January 2025
Center for Autoimmune Musculoskeletal and Hematopoietic Diseases, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, Manhasset, New York, 11030, USA.
Background: The process of B cell activation and plasma cell (PC) formation involves morphological, transcriptional, and metabolic changes in the B cell. Blocking or reducing PC differentiation is one approach to treat autoimmune diseases that are characterized by the presence of pathogenic autoantibodies. Recent studies have suggested the potential of myricetin, a natural flavonoid with anti-inflammatory and antioxidant properties, to block or reduce PC differentiation.
View Article and Find Full Text PDFTherapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
Ann Rheum Dis
January 2025
Academic Department of Rheumatology, Kings College London, London, UK. Electronic address:
Multiple clinical trials for rheumatoid arthritis (RA) prevention have been completed. Here, we set out to report on the lessons learnt from these studies. Researchers who conducted RA prevention trials shared the background, rationale, approach and outcomes and evaluated the lessons learnt to inform the next generation of RA prevention trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!